FIA
RXRX icon

FNY Investment Advisers’s Recursion Pharmaceuticals RXRX Stock Holding History

FNY Investment Advisers’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1K Buy
+298
New +$992 ﹤0.01% 812
2025
Q4 		– Sell
-231
Closed -$1K – 1399
2025
Q3 		$1K Buy
+231
New +$1.21K ﹤0.01% 1179

Other funds holding RXRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
IEFM
IQ EQ Fund Management Dublin 2, Ireland $1.57B AUM 40.42% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $11.7B AUM 87.29% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return

FNY Investment Advisers's RXRX Position: Q1 2026 in Review

FNY Investment Advisers sold out of Recursion Pharmaceuticals (RXRX) in Q1 2026, closing a stake of 3,444 shares — an estimated $14K sold.

FNY Investment Advisers first reported a position in RXRX in Q1 2024 and held it in 5 quarters. The position peaked at $20K in Q3 2025. 335 funds tracked by Wall St. Rank hold RXRX as of Q1 2026.

  • FNY Investment Advisers reported no remaining Recursion Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • FNY Investment Advisers sold 3,444 Recursion Pharmaceuticals shares in Q1 2026, an estimated $14K.
  • FNY Investment Advisers first reported a position in Recursion Pharmaceuticals in Q1 2024 and held it in 5 quarters.
  • FNY Investment Advisers's Recursion Pharmaceuticals position peaked at $20K in Q3 2025.
  • 335 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2026.

Based on FNY Investment Advisers's 13F filing for Q1 2026, filed 15 Apr 2026.